Journal of Alzheimer's Disease
Published on Journal of Alzheimer's Disease (https://www.j-alz.com)

Home > Tau in Alzheimer disease and related tauopathies.

TitleTau in Alzheimer disease and related tauopathies.
Publication TypeJournal Article
Year of Publication2010
AuthorsIqbal, K, Liu, F, Gong, C-X, Grundke-Iqbal, I
JournalCurr Alzheimer Res
Volume7
Issue8
Pagination656-64
Date Published2010 Dec
ISSN1875-5828
KeywordsAlzheimer Disease, Animals, Humans, Phosphorylation, tau Proteins, Tauopathies
Abstract

Tau is the major microtubule associated protein (MAP) of a mature neuron. The other two neuronal MAPs are MAP1 and MAP2. An established function of MAPs is their interaction with tubulin and promotion of its assembly into microtubules and stabilization of the microtubule network. The microtubule assembly promoting activity of tau, a phosphoprotein, is regulated by its degree of phosphorylation. Normal adult human brain tau contains 2-3 moles phosphate/mole of tau protein. Hyperphosphorylation of tau depresses this biological activity of tau. In Alzheimer disease (AD) brain tau is ~three to four-fold more hyperphosphorylated than the normal adult brain tau and in this hyperphosphorylated state it is polymerized into paired helical filaments ([PHF) admixed with straight filaments (SF) forming neurofibrillary tangles. Tau is transiently hyperphosphorylated during development and during anesthesia and hypothermia but not to the same state as in AD brain. The abnormally hyperphosphorylated tau in AD brain is distinguished from transiently hyperphosphorylated tau by its ability (1) to sequester normal tau, MAP1 and MAP2 and disrupt microtubules, and (2) to self-assemble into PHF/SF. The cytosolic abnormally hyperphosphorylated tau, because of oligomerization, unlike normal tau, is sedimentable and on self-assembly into PHF/SF, loses its ability to sequester normal MAPs. Some of the tau in AD brain is truncated which also promotes its self-assembly. Tau mutations found in frontotemporal dementia apparently promote its abnormal hyperphosphorylation. Thus, the AD abnormally hyperphosphorylated tau (1) is distinguishable from both normal and transiently hyperphosphorylated taus, and (2) is inhibitory when in a cytosolic/oligomeric state but not when it is self-assembled into PHF/SF. Inhibition of abnormal hyperphosphorylation of tau offers a promising therapeutic target for AD and related tauopathies.

Alternate JournalCurr Alzheimer Res
PubMed ID20678074
PubMed Central IDPMC3090074
Grant ListAG019158 / AG / NIA NIH HHS / United States
AG028538 / AG / NIA NIH HHS / United States
AG27429 / AG / NIA NIH HHS / United States
R01 AG019158 / AG / NIA NIH HHS / United States
R01 AG019158-10 / AG / NIA NIH HHS / United States
R01 AG028538 / AG / NIA NIH HHS / United States
R01 AG028538-05 / AG / NIA NIH HHS / United States
Top50 Topics: 
Tau, Diagnosis
E-mail Icon
Comment Icon
  • Comment
Bookmark Icon Bookmark Recommend Icon
  • 10 members recommend
Follow Icon Follow
  • Comment
| Bookmark |
  • 10 members recommend
| Follow

Source URL: https://www.j-alz.com/content/tau-alzheimer-disease-and-related-tauopathies